TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
OTC · EAPH · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Parallel Industries Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Parallel Industries Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Currently, Parallel Industries Inc. does not conduct substantial business operations. Historically, the company was involved in developing and commercializing various topically applied medications to treat cancer, alongside other therapeutic solutions for a range of medical conditions. Its strategic emphasis has typically covered the entire pharmaceutical process: from development and licensing to manufacturing and marketing of both prescription and over-the-counter products. Established in 1997, the firm is headquartered in Toronto, Canada, and was formerly known as Easton Pharmaceuticals Inc. before rebranding as Parallel Industries Inc. in December 2020.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
CA$4.40+CA$0.10 (+2.33%)
Medicure Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.11% below the high.
$0.00$0.00 (0.0%)
American Green, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.67% below the high.
$0.00$0.00 (0.0%)
Endexx Corporation’s quoted price sits in the lower half of its reported 52-week range, 99.75% below the high.
$0.00$0.00 (0.0%)
Creative Edge Nutrition, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
ARYx Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
OWC Pharmaceutical Research Corp.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
